BSE filing, BSE: 544529. Summary written from the filing by ALFA Finder's alert engine.
Aptus Pharma Ltd: key numbers
- Share price
- ₹470.30
- Market cap
- ₹806.6 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 174.6×Sector 41.3×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Preferential Issue
Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.
- Value
- ₹44.78 Cr
Aptus Pharma Investor Presentation: Key Takeaways
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.1 Cr · +200.0% YoY
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months
Other results update announcements
All →Steel Exchange India Results Update
Steel Exchange India Ltd reported a nine-fold surge in Q2 FY27 PAT to ₹18 Crore. Revenue rose 46% to ₹343 Crore alongside a ₹102 Crore debt reduction.
- quarterly production
- 69617.42 MT
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
SJS Enterprises Results Update
S.J.S. Enterprises reported record quarterly revenue of Rs. 282.73 Crore, up 16.9% YoY. Net profit for Q2FY27 rose 34.8% YoY to Rs. 58.33 Crore.
- Value
- ₹282.7 Cr
Meghmani Organics Results Update
MOL reported Q2 FY27 revenue of ₹658.2 crore, up 18% YoY, with net profit of ₹45.3 crore. EBITDA margin eased to 10.8% on elevated input costs.
GPT Infraprojects Results Update
GPT Infraprojects reported Q2 FY27 revenue of ₹291.4 crore and PAT of ₹18.3 crore. Order inflow was ₹1,491 crore; interim dividend of ₹1 declared.
- Order book
- ₹5,373 Cr
Indo Count Industries Results Update
Indo Count reported record Q2 FY27 income of ₹1,699 Cr and PAT of ₹132 Cr. H1 EBITDA grew 73% YoY to ₹420 Cr.